The Global Healthcare Exits Report

A data-driven review of 2014’s private healthcare company IPO and M&A activity.

Using CB Insights data, this report analyzes the global trends in healthcare exits for 2014. If you’re interested in the life sciences/healthcare space, this report is a must-read and highlights exit trends, top investors, acquirers, and more.

Below is a high-level summary of some of the report’s highlights. For all of the findings, download the entire report. It’s free.

2014: 775 Healthcare M&A Transactions, 135 Healthcare IPOs, and nearly $110B in disclosed exit valuations

Q1 2014 kicked off a big year for healthcare IPOs, which saw nearly 30 or more IPOs in each successive quarter and totaled $109.5B in disclosed valuations for all exits. Compared to H1 2014, H2 2014 saw M&A activity tick up with 16% more private healthcare acquisitions. Of the overall exits, 73% of all disclosed healthcare exits were under $300M, while 16 healthcare companies were acquired for or went public for more than a billion dollars including Juno Therapeutics, Seragon Pharmaceuticals and Alios BioPharma.

More VC-Backed Healthcare IPOs than M&A Transactions

Of the total number of Healthcare IPOs this year, less than 19% were venture backed. The number of VC-backed healthcare exits amounted to nearly 170 in 2014, with IPOs slightly beating out M&A transactions. July was the most active month, with 25 VC-backed exits including SAGE Therapeutics and Avalanche Biotechnologies.

20 Largest U.S. VC-Backed Healthcare Exits Take $13.9B In Value

• Juno Therapeutics
• Alios Biopharma
• Seragon Pharmaceuticals
• Labrys Biologics
• Kite Pharma
• Ultragenyx Pharmaceutical
• Ulthera
• iPierian
• Topera Medical
• Civitas Therapeutics
• PreCision Dermatology
• Versartis
• Pneumrx
• CardioMems
• SAGE Therapeutics
• Coherus BioSciences
• Nevro
• Small Bone Innovations
• InnoPharma
• Avalanche Biotechnologies

The Most Exited Healthcare Investors of 2014

Among VC firms, New Enterprise Associates had the most exits in healthcare companies in 2014. Venrock also notched an impressive year with healthcare exits including Juno, Coherus, Avalanche and Celladon. On the corporate side of investments, SR One, the corporate venturing unit of GlaxoSmithKline, topped all corporate investors by exit count in 2014. The top 5 was rounded out by Novo Ventures, J&J Development Corp, Novartis Venture Funds and Pfizer Venture Investments, respectively.